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Transient Intermittent Lymphocyte Activation Is
Responsible for the Instabilit of Angina
Gian Gastone Neri Serneri, MD; Rosanna Abbate, MD; Anna Maria Gori, BS;
Monica Attanasio, BS; Francesca Martini, BS; Betti Giusti, BS; Piero Dabizzi, MD;
Loredana Poggesi, MD; Pietro Amedeo Modesti, MD; Francesco Trotta, MD; Carlo Rostagno, MD;
Maria Boddi, MD; and Gian Franco Gensini, MD
Background. Blood clotting activation is an important component of the inflammatory response; the
outbursts of unstable angina are usually associated with increased thrombin formation and coronary
mural thrombosis.
Methods and Results. To investigate 1) whether monocyte activation is responsible for the enhanced
thrombin formation during bursts of unstable angina and 2) what mechanism(s) might be responsible for
monocyte activation, we studied patients with unstable angina (n=31), stable effort angina (n=23), left
endoventricular thrombosis (n=8), and control subjects (n=44), measuring plasma fibrinopeptide A
(FPA) levels and the capacity of monocytes to express procoagulant activity (PCA) and of lymphocytes to
modulate this expression. Patients with unstable angina and patients with endoventricular thrombosis
had significantly (p<0.0001) higher FPA plasma levels than patients with effort angina and control
subjects. However, only monocytes from unstable angina patients expressed significantly increased PCA
characterized as tissue factor-like activity (units/105 monocytes, median and range; 120, 1.1-463.2 versus
10.8, 0.8-39.1 in control subjects; p<0.0001 versus the other groups). When 14 patients with unstable
angina were restudied 8-12 weeks later, they showed neither elevated plasma FPA levels nor monocyte
PCA. In unstable angina patients, there was a correlation between FPA and PCA (r=0.56,p<0.001). For
expression of PCA by monocytes, both an incubation of at least 2 hours with lymphocytes and direct
monocyte-lymphocyte contact were needed. In reconstitution and cross-mixing experiments, only lym-
phocytes from patients with active unstable angina induced the expression ofPCA by monocytes from both
control and patient groups.
Conclsions. The results demonstrate that the increased thrombin formation in unstable angina patients
is due to the expression of tissue factor-like activity by activated monocytes. The monocyte activation
appears to be a part of a lymphocytic cell-instructed response intermittently triggered by unknown
factors. (Circulation 1992;86:790-797)
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ncreased thrombin generation, evaluated as raised
fibrinopeptide A (FPA) plasma levels, almost in-
variably occurs during outbursts of unstable angi-
na.1-3 Coronary mural thrombi have been frequently
detected in angiographic,4-7 angioscopic,8 and postmor-
tem studies.9 Plaque fissuring followed by platelet acti-
vation and contact of flowing blood with local prothrom-
botic substrates are the most widely proposed
mechanisms for the increased thrombin formation and
the beginning of the acute thrombotic event of unstable
angina.8-12 However, doubts have arisen about plaque
fissuring as a direct cause of either the increased
thrombin formation or development of mural thrombo-
sis because fissured plaques can be found in 10% of
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individuals dying of noncardiac causes,'3,14 and, not
infrequently, neither intimal lesions nor thrombi can be
found in patients who died because of unstable angina.'s
Moreover, no beneficial clinical effects have been ob-
tained by thrombolytic treatment of patients with unsta-
ble angina,16-20 indicating that mural thrombosis does
not play a major role in the pathogenesis of unstable
angina. There is clear-cut evidence that activation of
blood coagulation is an important component of the
inflammatory response, especially during the immune
response.21-25 Coronary atherosclerotic plaques contain
abundant lymphoplasma cell and monocyte-macro-
phage infiltrates,26-29 which are found much more fre-
quently to be markedly increased into the site of
plaques in subendothelium and in perivascular nerves
of unstable angina patients with fatal outcome than of
patients with effort angina who died of noncardiac
causes, even with the same degree of coronary luminal
narrowing.30-32
After in vitro exposure to immune or nonimmune
stimuli, monocytes express tissue factor on their sur-
faces24,33-40 and can specifically activate blood clotting.
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Monocyte-macrophage activation resulting in procoag-
ulant activity (PCA) formation might contribute to the
increased thrombin generation and, most importantly,
might be a causative link between inflammation and
instability of angina. The aims of the present study
were to investigate 1) whether monocyte activation
occurs during bursts of unstable angina, 2) whether it
may be responsible for activation of clotting and
enhanced thrombin formation in these patients, and 3)
what mechanism(s) might be responsible for monocyte
activation.
Methods
Study Population
We studied 31 consecutive patients aged less than 70
years with primary unstable angina (type IIB and IIIB,
according to Braunwald41) and 23 patients with stable
effort angina. We studied 35 apparently healthy subjects
of equivalent ages with normal lifestyles and without
any limitations in physical activity (healthy controls),
nine patients with chest pain caused by noncardiac
causes (three intercostal fibrositis, two spontaneous
pneumothorax, and four motor disorders of the esoph-
agus), and eight patients with endoventricular thrombi
complicating idiopathic dilatative cardiomiopathy as
control subjects. This last group represented control
subjects with activated blood clotting. Unstable angina
was defined as chest pain occurring at rest or on
minimal effort (washing, speaking, combing) without
any increase in the creatine kinase MB fraction, with
ECG evidence of myocardial ischemia (transient ST
segment displacement >0.1 mV during chest pain), and
angiographic evidence of coronary artery disease. Pa-
tients were continuously monitored by ECG for the first
3 days before blood sampling, and coronary angiogra-
phy was performed after the blood specimen was drawn.
Stable effort angina was defined according to the fol-
lowing criteria: 1) typical anginal pain on effort and no
anginal attacks at rest during at least the previous 3
months, 2) no asymptomatic ischemic episodes at rest
during 3-day Holter monitoring, 3) stable ischemic
threshold during at least three stress exercises in the
week preceding the study, and 4) angiographic evidence
(at least one stenosis >70%) of coronary artery disease.
Patients with effort angina had been on nitrates and
calcium antagonists for at least 1 week. Patients were
excluded from the study if they had enzymatic or ECG
evidence of myocardial infarction, clinical evidence of
recent infections, or were suffering from diabetes, im-
munological disorders, or neoplastic disease. Patients
were also excluded if they had undergone surgical or
invasive procedures in the month preceding the study.
Patients were taking no drugs that would interfere with
platelet function or blood clotting such as heparin, oral
anticoagulants, or antiplatelet drugs before the blood
sampling. In 10 unstable angina patients, mononuclear
PCA was investigated before and during heparin admin-
istration (priming dose, 5,000 IU followed by 1,000
IU/hr42). Blood was drawn in the morning after over-
night fasting and within 48 hours of the most recent
episode of chest pain. Fourteen of 31 patients with
unstable angina were restudied after a convalescent
period of at least 8-12 weeks, at a time when they had
been free of symptomatic or asymptomatic (Holter
monitoring) ischemic episodes for at least 2 weeks. Nine
stable effort angina patients and nine normal control
subjects were also restudied. All patients gave their
informed consent to use part of their blood samples for
an experimental study.
Experimental Procedure
Cell preparations. Mononuclear cells were obtained
from peripheral citrated blood. Briefly, platelets were
removed by two centrifugations, and mononuclear cells
were separated by density gradient centrifugation43 and
washed twice with phosphate-buffered saline-EDTA to
eliminate further platelet contaminants and finally were
resuspended (lx107 cells/ml) in RPMI-1640 plus gen-
tamicin (100 ,g/ml). Mononuclear cells were more than
98% viable by trypan blue exclusion and contained
<2% polymorphonuclear leukocytes and <1% plate-
lets. Cells were identified by a-naphthylacetate esterase
staining44 and by flow cytometric analysis by using
monoclonal antibodies (OKM14, OKPanB, OKT3, Or-
tho Diagnostic Systems, Milan, Italy). The percentage
of monocytes was 20.4+1.7% in mononuclear prepara-
tions. Pure preparations (98%) of both monocytes and
lymphocytes were obtained by incubating mononuclear
cell suspensions on precoated Petri dishes for 1 hour.45
To look for a role of lymphocytes in inducing the
expression of PCA by monocytes, PCA was assayed
separately in pure monocyte and pure (98%) lympho-
cyte preparations and in cell suspensions obtained by
mixing lymphocytes from patients or control subjects
with monocytes from control subjects or patients. In
addition, purified monocytes were incubated in the
presence of lymphocytes in a coculture system (Costar
Transwell-Cal), preventing direct cell-cell contact. In
the cross-mixing experiments, the relative proportion of
lymphocytes to monocytes was 4:1, which has been
found optimal for the collaborative effect of lympho-
cytes on monocytes.46 We assayed the effects of super-
nates obtained from pure lymphocytes incubated for 4
hours. These supernates were added to pure monocyte
suspensions, incubated for 4 hours, and PCA was as-
sayed. All reagents were negative for endotoxin contam-
ination at the level of 0.005 ng/ml (Limulus amoebocyte
lysate assay, E-Toxate, Sigma Chemicals, St. Louis,
Mo.).
Assay and characterization of procoagulant activity.
Cell preparations were incubated for 0, 2, 4, 8, 12, and
18 hours at 37°C in a humidified 5% CO2 atmosphere
and disrupted by freezing, thawing, and sonicating. PCA
of cells was assayed by one-stage plasma recalcification
time47 and expressed in arbitrary units (units/105 mono-
cytes). In preliminary experiments, the PCA was char-
acterized as tissue factor by evaluating its sensitivity to
phospholipase C (Calbiochem, San Diego, Calif.),48
Concanavalin A (Sigma),49 and cysteine protease inhib-
itor (HgCl2)50 and by using factor VII and factor X
deficient plasmas. To rule out direct interference of
heparin administered to the patients with the assay of
the PCA produced by mononuclear cell suspensions,
heparin was added to the assay system in specially
designed experiments just before determination at a
concentration of the same order of that in vivo (0.2-0.3
IU/ml final concentration). Under these experimental
conditions, heparin did not influence the assay of PCA.
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TABLE 1. Characteristics of the Subjects
Healthy Noncardiac Effort Unstable Endoventricular
controls chest pain angina angina thrombosis
No. 35 9 23 31 8
Men 24 6 17 22 5
Women 11 3 6 9 3
Age (years) 51.7+13.2 55.9±9.8 53.8±7.8 54.6±9.1 58.6±5.8
Weight (kg) 72.5±9.5 69.8±8.2 69.1±7.4 70.2±6.5 71.6±6.8
Cholesterolemia (mmol/l)* 4.9±0.7 5+0.8 5.2±0.7 5.1+±0.6 5.3±0.6
Blood pressure (mm Hg)
Systolic 135+13 138+12 143+15 140±16 139±11
Diastolic 82±6 80±7 80±6 79±6 81±6
Mean angiographic score ... ... 16.4±3.9 15.9±5.9
Values are mean±SD.
*To convert cholesterol values to milligrams per deciliter, multiply by 38.67.
Plasma fibrinopeptide A. Plasma FPA assay was per-
formed by the ELISA method according to Gaffney et
al51 and Soria et al,52 using commercial kits kindly
supplied by Boehringer Biochemia (Milan, Italy). The
intra-assay and interassay coefficients of variation were
5.9% and 7.8%.
Coronary Angiography
Coronary angiography was performed by Judkin's
technique. The occurrence and severity of coronary
angiographic lesions were evaluated from at least three
projections by the score suggested by the American
Heart Association.53
Statistical Analyses
The analyses were performed by an IBM PS2/70
computer and BMDP statistical software. Demographic
data were analyzed by ANOVA. Values of FPA and
PCA were initially assessed for normality by the kurtosis
test. On the basis of these results, nonparametric pro-
cedures were used to compare data from the various
groups. Unless otherwise indicated, results are given as
medians and ranges. The nonparametric Kruskal-Wallis
test for one-way ANOVA (H test) was used for the
differences among the various groups; the Wilcoxon
rank-sum test for unpaired and paired data was used for
comparisons between individual groups. For the corre-
lation analysis, Spearman's rank correlation coefficient
was used. The PCA was calculated by regression anal-
ysis. All probability values reported are two-tailed, with
values of less than 0.05 considered statistically
significant.
Results
Clinical Characteristics
Characteristics of patients and control subjects are
shown in Table 1. All patients with unstable angina had
had anginal attacks and silent ischemic episodes the first
day after hospital admission and were on nitrates plus
calcium antagonists. The number of angina attacks over
the 3-day monitoring period averaged 3.4±+5.9
(mean+SEM) per patient per day, and the silent isch-
emic episodes averaged 7.2+5.3 per patient per day.
All patients with both unstable angina and stable
effort angina had angiographic evidence of coronary
artery disease (Table 1). There were no significant
differences in severity or in extent of angiographic
coronary lesions between the two groups of patients
(Table 1).
Thrombin Formation
All except one patient with unstable angina showed
increased thrombin generation, as revealed by elevated
plasma levels of FPA (Figure 1). FPA plasma levels
were also elevated in the seven patients receiving ni-
trates and calcium antagonists who had not had any
ischemic episodes (Holter monitoring) for at least 36
hours before blood sampling. FPA plasma levels of
unstable angina patients (median, 7.1 ng/ml; range,
1.5-14.1) were similar to those found in patients with
intraventricular thrombosis (median, 8.2 ng/ml; range,
5.3-11.4) but significantly higher than those of control
subjects (healthy control subjects: median, 1.8 ng/ml;
range, 0.8-3.7 [p<0.0001]; noncardiac chest pain pa-
tients: median, 1.7 ng/ml; range, 1.5-3.4 [p<0.0001])
(Figure 1). Unlike the patients with unstable angina,
only four of 23 patients with stable effort angina had
increased levels of FPA in plasma. The FPA values of
this group of patients did not differ from those of the
healthy control subjects (median, 1.7 ng/ml; range,
1.5-4.6) (Figure 1). All of the 14 patients with unstable
angina who were restudied 8-12 weeks later, when they
were spontaneously free of myocardial ischemia, had
significantly lower FPA plasma levels (p<0.001) than
their original values, at this time not differing from
controls (Figure 2).
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FIGURE 1. Plot offibrinopeptide A (FPA) plasma concen-
trations. Lines indicate median values; shaded area indicates
control range.
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FIGURE 2. Plots show fibrinopeptide A (FPA) (left panel) and procoagulant activity (PCA) (right panel) in the same patients
when sufferingfrom myocardial ischemic episodes (A) and after 8-12 weeks when free from ischemic episodes (B). Lines indicate
median values; shaded area indicates control range.
Mononuclear Cell Procoagulant Activity
There were no significant differences in the monocyte
content of the mononuclear cell preparations from the
different groups (F=0.13, NS). The time courses of the
reaction leading to the formation of PCA by mononu-
clear cells are reported in Figure 3. In all the assays, the
highest PCA was expressed after 4 hours and did not
increase during the remaining 14 hours of incubation
(Figure 3).
By the procedures described in "Methods," mononu-
clear cell PCA was characterized as tissue factor-like
activity (data not shown). Mononuclear cells evaluated
immediately after separation from blood expressed only
scanty amounts of PCA, without significant differences
among the five groups of subjects (H= -1.85, p =0.18;
Table 2). Conversely, after a 4-hour period of incuba-
tion, mononuclear cells from all except two patients
with unstable angina showed elevated amounts of PCA
(median, 120.1 units/105 monocytes; range, 1.1-463.2
units/105 monocytes), whereas the mononuclear cells
150-
100
0
0
0 2 4 8 2 18
Incubation time (hours)
FIGURE 3. Plot shows time course ofprocoagulant activity
(PCA) expressed by mononuclear cell preparations (bars
indicate standard deviation) (n=10). Closed squares, unsta-
ble angina patients; closed circles, effort angina patients; open
squares, control subjects.
from the control subjects and patients with endoventric-
ular thrombosis or stable effort angina produced PCA in
trace amounts (Figure 4) without further increase.
Mononuclear cells from the seven patients who did not
have angina attacks in the 24 hours preceding blood
sampling also showed elevated PCA levels (median,
128.8 units/105 monocytes; range, 101.1-218.6 units/105
monocytes). Pure (98%) neutrophil, lymphocyte, and
monocyte preparations from unstable angina patients
and from control subjects did not develop any significant
PCA during an 18-hour incubation period (data not
shown). In contrast to the first determinations, mono-
nuclear cells from the 14 patients with unstable angina
who were restudied 8-12 weeks later, when angina free,
expressed only negligible amounts of PCA not different
from that expressed by control subjects or patients with
stable angina (Figure 2). In the group of patients with
unstable angina investigated in both active and inactive
phases, there was good correlation between FPA
plasma levels and the amount of PCA produced by
mononuclear cells (r=0.56, p<0.001) (Figure 5). Con-
versely, there were no significant relations between
plasma FPA levels or the amount of PCA and the
severity of coronary angiographic lesions (r=0.08 and
r=0.07, respectively, NS). The addition of plasma (1:10)
from the control subjects or from angina patients to the
incubation medium increased the expression of mono-
cyte PCA without any significant difference between
patients or controls (data not shown).
TABLE 2. Procoagulant Activity (Units/105 Monocytes) Formed
by Mononuclear Cells Immediately After Separation
Non- Endo-
Healthy cardiac Effort Unstable ventricular
subjects chest pain angina angina thrombosis
(n=35) (n=9) (n=23) (n=31) (n=8)
Median 0.28 0.29 0.30 0.33 0.30
Range 0.1-0.9 0.1-0.7 0.1-1.0 0.1-3.7 0.1-0.8
For calculating median values, the value of 0.1 was attributed to
samples below the detection limit.
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FIGURE 4. Plot shows procoagulant activity (PCA) of
mononuclear cell preparations after 4-hour incubation. Lines
indicate median values; shaded area indicates control range.
Reconstitution and Cross-Mixing Experiments
The addition of pure (98%) lymphocyte preparations
from patients with unstable angina to pure (98%)
monocyte preparations from control subjects or from
patients with stable effort angina induced the formation
of significant amounts of PCA in 4 hours of incubation
(Figure 6). On the contrary, the addition of lymphocytes
from control subjects or from patients with endoventric-
ular thrombosis or from patients with stable effort
angina to monocytes from control subjects or from
unstable angina patients induced expression of insignif-
icant PCA (Figure 6). Thus, only lymphocytes from
patients with unstable angina were able to induce the
expression of tissue factor-like activity in pure mono-
cyte preparations. However, no significant PCA was
expressed by the addition of lymphocyte supernates to
monocytes or when direct monocyte-lymphocyte con-
tact was prevented.
Effects of Heparin on Plasma Fibrinopeptide A and
Mononuclear Procoagulant Activity
Ten patients with active unstable angina were treated
by continuous intravenous heparin infusion (1,000 IU/
hr). Twelve hours after the start of heparin infusion,
FPA plasma levels were significantly lower in all pa-
tients but had not returned to the normal range. Simul-
taneously, the expression of tissue factor-like activity by
mononuclear cells decreased from 129.6 units/10 mono-
cytes (range, 46-463.2 units/105 monocytes) to 27.4
units/105 monocytes (range, 8.7-54.5 units/105 mono-
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FIGURE 5. Plot shows relation between fibrinopeptide A
(FPA) and procoagulant activity (PCA) in unstable angina
patients investigated in both active and inactive phases.
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FIGURE 6. Bargraph shows effect of cellular interactions on
procoagulant activity (PCA) (mean- SD). L, lymphocytes; M,
monocytes; C, controls; E.A., effort angina; E. T., endoven-
tricular thrombosis; U.A., unstable angina; C+E.A., n=9;
C+UA, n=14; U.A.+E.A., n=9; U.A.+E.T., n=5.
cytes) after a 4-hour incubation period (p<0.001) (Ta-
ble 3). However, heparin administration did not affect
the capacity of lymphocytes to induce procoagulant
expression by monocytes because pure preparations of
lymphocytes from patients receiving heparin were still
able to induce the expression of PCA in monocytes from
control subjects (Table 3), suggesting that heparin only
blocked the expression of PCA by monocytes.
Discussion
Our results indicate that circulating lymphocytes from
patients with active unstable angina but not from con-
trol subjects or patients with stable effort angina were
able to induce the expression of tissue factor activity by
monocyte preparations obtained from both control sub-
jects and patients. The lymphocyte activation and the
expression of PCA by monocytes did not appear to be
epiphenomena of the angina, because they were demon-
strable also in patients temporarily without angina
attacks because of antiangina treatment, or a conse-
quence of thrombotic processes or blood clotting acti-
vation, because only low or very low levels of monocyte
PCA were found in the monocytes from patients with
endoventricular thrombosis. The lymphocyte activation
TABLE 3. Effect of Heparin Infusion :1,000 lU/hr for 12 Hours
on Mononuclear Cell Procoagulant Activity and Fibrinopeptide
A Levels
Before heparin After heparin
infusion infusion p
Mononuclear cell
procoagulant activity
(units/105 monocytes)
Unstable angina
lymphocytes plus
unstable angina 129.6 27.4
monocytes (n=10) 46-463.2 8.7-54.5 <0.001
Unstable angina
lymphocytes plus
control monocytes 110.9 104.4
(n= 10) 55.8-202.5 56.3-177.2 =0.9
Control lymphocytes
plus unstable angina 15.9 15.6
monocytes (n=6) 12.8-34.6 12.9-33.1 =0.6
Fibrinopeptide A
(ng/ml), unstable
angina patients 8.1 3.6
(n=10) 4.2-17.3 1.3-5.1 <0.001
Values are expressed as median and range.
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and the expression of monocyte PCA appear to be
distinct features of active unstable angina and not a
consequence of coronary artery disease per se, because
they were not detectable in the same patients restudied
8-12 weeks later, at which time they had no angina.
Some evidence indicates that the lympho-monocyte
activation can be responsible, at least in part, for the
augmented thrombin generation in patients with unsta-
ble angina, because FPA plasma levels were elevated
only in patients with mononuclear PCA formation, and
there was a good relation between FPA plasma levels
and the formation of tissue factor. Moreover, heparin
administration simultaneously reduced FPA levels and
monocyte PCA. Obviously, the monocyte mechanism
does not exclude other possible mechanisms such as
plaque disruption, platelet activation, or contact of
flowing blood with thrombogenic substrate of the arte-
rial wall. The results of reconstitution and mixing
experiments indicate that the lymphocyte activation is
the crucial moment for the PCA formation by mono-
cytes. Thus, the activation of the lymphocytes and the
elevated monocyte PCA and FPA plasma levels in
patients with active unstable angina appear to be an
expression of an acute transient inflammatory state, in
agreement with the knowledge that activation of blood
coagulation has long been recognized to be an impor-
tant component of the inflammatory response, espe-
cially during the immune response.21-25 Although only
anatomical studies can be conclusive, the reported
elevation of C-reactive protein in active coronary artery
disease54 and the elevated density of circulating mono-
cyte-macrophages with major histocompatibility com-
plex class II antigen HLA-DR55 support this statement.
A special issue is whether monocyte activation occurs
in blood circulation or in the coronary arterial wall. The
formation of the PCA by monocytes appears as a
response to triggered lymphocyte-monocyte contact
rather than to soluble lymphokines56-58 because no
significant PCA was expressed when direct monocyte-
lymphocyte contact was prevented or after addition of
lymphocyte supernates to monocyte preparations. The
mononuclear cell preparations formed only negligeable
amounts of PCA in the first 30-60 minutes of incuba-
tion, indicating that monocytes were not sufficiently
activated to produce PCA in circulating blood. More-
over, monocytes expressed their PCA only in the pres-
ence of lymphocytes and needed contact with these cells
and some hours of incubation. These observations
suggest that monocyte activation and the expression of
PCA in vivo are very likely to occur not in the circulat-
ing blood but prevalently extravascularly. That mono-
cyte activation and thrombin formation mainly occur in
the coronary vessel wall also seems supported by the
failure of heparin infusion to fully normalize FPA levels.
Several similar observations reported for cancer pa-
tients given heparin support the extravascular site of the
stimulus for monocytes activation and elevated FPA
levels.59-61 In the coronary atherosclerotic plaque, lym-
phocytes and monocytes are closely associated with one
another in the subendothelial intimal space31,3262,63 in
addition to the adventitia,30,32 and in human plaques,
tissue factor64 and tissue factor-producing cells have
been identified by in situ hybridization.65 Moreover,
there is evidence that monocyte-macrophages present in
the coronary atherosclerotic plaque from patients with
unstable angina but not in those with effort angina are
activated because these cells have been found to syn-
thesize tumor necrosis factor,66-68 whose production is
dependent on the presence of proliferating T cells.69
The present findings do not clarify whether the un-
known stimulus that leads to the activation of lympho-
cytes acts systemically or is restricted to lymphocytes
inside the plaque. Similarly, we do not know whether
the activated lymphocytes and monocytes from patients
with unstable angina are originally inside the vessel wall
and then circulate in the blood as a result of plaque
rupture or fissuring, although this condition is not
necessary because experimental evidence indicates a
continuous passage of lymphocytes and monocytes from
blood to the vessel wall.26,7071
Conclusions
Whatever the mechanism(s) and sites of activation,
our results support the hypothesis that the outburst of
unstable angina represents an acute transient inflamma-
tory state caused by lymphocyte activation intermit-
tently triggered in response to unknown factors. Thus,
the primary event in the instability of angina could be
the exposure of lymphocytes to an inducer that triggers
a series of reactions leading to monocyte activation,
increased thrombin generation, and thrombus forma-
tion, priming the instability of coronary artery disease.
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